Clinical Trial Search

Primary: Number of Adverse Events After CAR 20/19-T Cell Infusion — 7; 4; 22 Serious Adverse Events

Primary: Documenting Adverse Events (AEs), Serious Adverse Events (SAEs), Dose Limiting Toxicities (DLTs) (Graded According to NCI-CTCAE Version 4.02) and Laboratory Parameters…

Primary: Overall Response (Complete Response + Partial Response) — 216; 94 Participants

Primary: Phase I: Incidence of Any DLT Attributed to DT2219 in the First Cycle — 1; 3; 0 events

Primary: Percentage of Participants With Adverse Events (AEs) — 89.6 percentage of participants

Primary: Number of Participants (Par.) Classified as Responders and Non-responders for Objective Response as Assessed by an Independent Endpoint Review Committee (IRC) in…

Primary: Number of Participants With Objective Response (OR) — 0; 1; 2; 0 participants

Primary: Percentage of Patients Assigned to Arm Latent Membrane Protein-specific T-cells (LMP-TC) With Successful LMP-specific T Cell Product Match, Were Treated Within Two Weeks…

Primary: Maximum Tolerated Dose (MTD) of Alemtuzumab — 30 mg

Primary: Percentage of Participants With 3-year Progression-free Survival (PFS) — 90 percentage of participants

Primary: Percentage of Enrolled Participants Who Actually Get Treated — 76.9 percentage of participants

Primary: Number of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma — 2; 3; 2; 3 Participants

Primary: Number of Participants With Confirmed Response, Including Participants With Complete Response (CR), Clinical Complete Response (CCR), and Partial Response (PR) — 72…

Primary: Number of Participants (Par.) With Confirmed Response as Assessed by the Investigator — 21; 8 participants

Primary: Complete Response Rate (CRR) — 73 Percentage of patients

Primary: Number of Participants (Par.) With Unconfirmed Response (Complete Response, Complete Response/Unconfirmed, or Partial Response), as Assessed by the Investigator — 30…

Primary: Progression-free Survival — 72 Percent

Primary: Area Under the Serum Concentration-time Curve From Day 1 to Week 4 (AUC[1-4]) — 1559.51; 1509.79 (μg*day)/mL

Primary: Number of Participants With Unconfirmed Response (Complete Response or Partial Response) and Unconfirmed Complete Response — 437; 238 Participants

Primary: Event-free Survival (EFS) — 9; NA Months

Primary: Clinical Response Rate — 2; 0; 1; 1 participants

Primary: Overall Response — 8; 14; 19 Participants

Primary: Area Under the Serum Concentration Time Curve From Zero to Day 7 (AUC0-7) of Obinutuzumab on Day 1, Cycle 1 — 1458; 1750; 1647 day*micrograms per milliliter

Primary: Maximum Tolerated Dose (MTD) — NA 10^6 CAR T cells

Primary: Percentage of Participants With Complete Response (CR) at End of Treatment Period — 31; 25 percentage of participants

Primary: Number of Participants Who Received Preparative Chemotherapy Followed by Cluster of Differentiation (CD)19-Chimeric Antigen Receptor (CAR): CD19 CAR T-cells With < Grade…

Primary: ORR — 88; 81 percentage of patients

Primary: Proportion of Responses (Complete Response or Partial Response) — 19.0; 42.9 percentage of participants

Primary: Event-free Survival (EFS) — 83 percentage of not experiencing EFS event

Primary: Progression-free Survival (PFS) at 2 Years — 69 percentage of participants